Table 1.
Nominated challenges in round 1 (n=470) | Completed all three rounds (n=336) | |
---|---|---|
Sex | ||
Female | 208 (44%) | 156 (46%) |
Male | 262 (56%) | 180 (54%) |
GBD super-region of main work* | ||
Sub-Saharan Africa | 146 (31%) | 104 (31%) |
High-income | 74 (16%) | 58 (17%) |
South Asia | 59 (13%) | 44 (13%) |
Southeast Asia, east Asia, and Oceania | 75 (16%) | 42 (13%) |
Latin America and Caribbean | 48 (10%) | 35 (10%) |
North Africa and Middle East | 40 (9%) | 32 (10%) |
Central Europe, eastern Europe, and central Asia | 28 (6%) | 21 (6%) |
GBD super-region of institution* | ||
High-income | 177 (38%) | 134 (40%) |
Sub-Saharan Africa | 104 (22%) | 74 (22%) |
South Asia | 52 (11%) | 37 (11%) |
Latin America and Caribbean | 38 (8%) | 27 (8%) |
North Africa and Middle East | 37 (8%) | 25 (7%) |
Southeast Asia, east Asia, and Oceania | 40 (9%) | 21 (6%) |
Central Europe, eastern Europe, and central Asia | 22 (5%) | 18 (5%) |
Main field of work† | ||
Clinician or practitioner | 200 (43%) | 126 (38%) |
Management or leadership in eye health | 116 (25%) | 89 (26%) |
Clinical research | 94 (20%) | 76 (23%) |
Eye health services research | 90 (19%) | 72 (21%) |
Education | 88 (19%) | 68 (20%) |
Epidemiology | 64 (14%) | 51 (15%) |
Implementing agency (including non-governmental organisation) | 58 (12%) | 46 (14%) |
Health service policy or planning (including Ministry of Health) | 58 (12%) | 44 (13%) |
Other research (vision science, genetic) | 37 (8%) | 24 (7%) |
Advocacy, corporate sector, or funder | 31 (7%) | 20 (6%) |
International institutions (eg, WHO, Pan American Health Organization, International Agency for the Prevention of Blindness) | 25 (5%) | 16 (5%) |
Patient group | 9 (2%) | 5 (1%) |
Data are n (%). GBD=Global Burden of Disease Study.
List of countries available in appendix 7 (p 1).
Participants could nominate up to two fields of work, hence percentages will add up to more than 100%.